28 januari 2026 Sweden
Diamyd Medical´s vd Ulf Hannelius presenterar bolagets kvartalsrapport och nuvarande status i bolaget.
Rapporten publicerades den 28 januari 2026. Producerat i samarbete med BioStock, moderator Cecilia Hallström.
|
26 januari 2026 Sweden
Diamyd Medical has strengthened its manufacturing platform through an expanded collaboration with APL in Umeå and a strategic partnership with NorthX Biologics in Matfors. The alliances integrate complementary expertise across the biopharmaceutical value chain, supporting the transition from late-stage clinical development to potential commercial production. At the same time, the initiative reinforces northern Sweden’s growing role as a center for advanced life-science manufacturing. Read the article here
|
23 januari 2026 Sweden
Diamyd Medical has strengthened its production capabilities through an expanded strategic alliance with APL and a new collaboration with NorthX Biologics. The partnership brings together complementary expertise in active substance production, fill and finish, and validation, centered around Diamyd Medical’s manufacturing site in Umeå. The initiative aims to support the transition from clinical development to commercial manufacturing while reinforcing northern Sweden as a hub for life science and advanced biologics production. Read the article here
|
13 januari 2026 Sweden
In an interview with BioStock, board member Karin Rosén discusses how Nobel Prize–recognized research on peripheral immune tolerance underpins Diamyd Medical’s strategy and its relevance for autoimmune diabetes. She also outlines what preserving patients’ own insulin production could mean for disease modification as the company approaches the interim phase III DIAGNODE-3 readout in March 2026. Read the article here
|
9 januari 2026 Sweden
In an interview with BioStock, CEO Ulf Hannelius and board member Karin Rosén discuss what accelerated timeline for its phase III study DIAGNODE 3 could mean going forward, what to expect from the preliminary readout in March 2026, and how the 2025 Nobel Prize in Medicine may be linked to Diamyd Medical’s work. See the interview here
|